​

Revance Therapeutics (RVNC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RVNC Stock Forecast

Revance Therapeutics (RVNC) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $20.78, with a high of $37.00 and a low of $6.66. This represents a 469.32% increase from the last price of $3.65.

- $8 $16 $24 $32 $40 High: $37 Avg: $20.78 Low: $6.66 Last Closed Price: $3.65

RVNC Stock Rating

Revance Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (52.63%), 9 Hold (47.37%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 9 10 Strong Sell Sell Hold Buy Strong Buy

RVNC Price Target Upside V Benchmarks

TypeNameUpside
StockRevance Therapeutics469.32%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$9.16
Last Closing Price$3.65$3.65$3.65
Upside/Downside--150.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25-17--8
Jan, 25-17--8
Dec, 24-18--9
Nov, 24168--15
Oct, 24169--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 17, 2024Vamil DivanMizuho Securities$6.66$5.9611.74%82.47%
May 10, 2024David AmsellemPiper Sandler$11.00$3.74194.12%201.37%
May 10, 2024Douglas TsaoH.C. Wainwright$11.00$4.29156.41%201.37%
May 10, 2024Vamil DivanMizuho Securities$8.00$3.73114.48%119.18%
Sep 20, 2023Serge BelangerNeedham$35.00$13.48159.64%858.90%
Jan 10, 2023Needham$38.00$30.4224.92%941.10%
Nov 16, 2022Barclays$37.00$23.7655.72%913.70%
Aug 25, 2022Jacob HughesWells Fargo$24.00$21.2612.89%557.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 13, 2024BarclaysEqual-Weightdowngrade
Aug 13, 2024H.C. WainwrightBuyNeutraldowngrade
Aug 12, 2024NeedhamBuyHolddowngrade
Aug 12, 2024Piper SandlerOverweightNeutraldowngrade
Aug 12, 2024William BlairOutperformMarket Performdowngrade
Aug 12, 2024GuggenheimBuyNeutraldowngrade
May 13, 2024William BlairOutperformOutperformhold
May 10, 2024Piper SandlerOverweightOverweighthold
May 10, 2024H.C. WainwrightBuyBuyhold
Sep 20, 2023NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.86$-4.25$-4.90$-3.83-----
Avg Forecast$-4.34$-3.22$-2.74$-2.28$-1.13$-0.69$-0.22$0.37$0.87
High Forecast$-3.91$-2.90$-2.43$-2.25$-1.11$-0.43$0.19$1.97$0.94
Low Forecast$-4.76$-3.53$-2.98$-2.31$-1.15$-0.95$-0.71$-1.46$0.77
Surprise %11.98%31.99%78.83%67.98%-----

Revenue Forecast

$0 $130M $260M $390M $520M $650M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.32M$77.80M$132.56M$234.04M-----
Avg Forecast$13.22M$75.60M$128.76M$226.40M$250.14M$320.07M$399.01M$483.55M$574.40M
High Forecast$14.20M$81.22M$137.38M$238.85M$254.10M$329.12M$407.18M$490.44M$608.73M
Low Forecast$12.21M$69.83M$117.59M$222.45M$246.17M$310.15M$390.84M$476.66M$524.22M
Surprise %15.91%2.90%2.96%3.37%-----

Net Income Forecast

$-400M $-280M $-160M $-40M $80M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-282.09M$-286.82M$-356.42M$-323.99M-----
Avg Forecast$-233.83M$-294.05M$-294.67M$-323.99M$-95.88M$-58.34M$-31.19M$-8.60M$73.60M
High Forecast$-187.06M$-235.24M$-235.74M$-259.19M$-94.09M$-36.36M$15.94M$166.48M$79.32M
Low Forecast$-280.60M$-352.86M$-353.60M$-388.78M$-97.67M$-80.32M$-59.79M$-123.79M$65.24M
Surprise %20.64%-2.46%20.96%------

RVNC Forecast FAQ

Is Revance Therapeutics stock a buy?

Revance Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Revance Therapeutics is a favorable investment for most analysts.

What is Revance Therapeutics's price target?

Revance Therapeutics's price target, set by 19 Wall Street analysts, averages $20.78 over the next 12 months. The price target range spans from $6.66 at the low end to $37 at the high end, suggesting a potential 469.32% change from the previous closing price of $3.65.

How does Revance Therapeutics stock forecast compare to its benchmarks?

Revance Therapeutics's stock forecast shows a 469.32% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Revance Therapeutics over the past three months?

  • February 2025: 0% Strong Buy, 12.50% Buy, 87.50% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 0% Strong Buy, 12.50% Buy, 87.50% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 11.11% Buy, 88.89% Hold, 0% Sell, 0% Strong Sell.

What is Revance Therapeutics’s EPS forecast?

Revance Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.13, marking a -70.50% decrease from the reported $-3.83 in 2023. Estimates for the following years are $-0.69 in 2025, $-0.22 in 2026, $0.37 in 2027, and $0.87 in 2028.

What is Revance Therapeutics’s revenue forecast?

Revance Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $250.14M, reflecting a 6.88% increase from the reported $234.04M in 2023. The forecast for 2025 is $320.07M, followed by $399.01M for 2026, $483.55M for 2027, and $574.4M for 2028.

What is Revance Therapeutics’s net income forecast?

Revance Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-95.879M, representing a -70.41% decrease from the reported $-324M in 2023. Projections indicate $-58.344M in 2025, $-31.191M in 2026, $-8.596M in 2027, and $73.6M in 2028.